Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases.
$4.88+5.86%
报价 2026-11-06
市值
$301.8M
EV
$316.4M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -56.6%
$4.61$11.25
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-07不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| KYTXKyverna Therapeutics, Inc. | $301.8M | +5.9% | +86.6% | 0% | – | – | – | |
| SLNSilence Therapeutics plc | $931.9M | +0.1% | – | 51% | – | – | – | |
| CAPRCapricor Therapeutics, Inc. | $521.2M | +4.7% | +18885.7% | 0% | – | 0.5x | – | |
| EDITEditas Medicine, Inc. | $394.7M | +0.8% | -41.9% | 56.9% | – | – | – | |
| LYELLyell Immunopharma, Inc. | $364.1M | -0.9% | -100.0% | -8,537% | – | – | – | |
| ALLOAllogene Therapeutics, Inc. | $359.3M | -4.6% | – | 0% | – | – | – | |
| AVIRAtea Pharmaceuticals, Inc. | $345.7M | +2.1% | -19.7% | 0% | – | – | – | |
| CTNMContineum Therapeutics, Inc. Class A Common Stock | $336.6M | +8.1% | +15.0% | 0% | – | – | – | |
| LXEOLexeo Therapeutics, Inc. Common Stock | $237.2M | -0.5% | -100.0% | 0% | – | – | – | |
| 同行中位数 | – | – | -30.8% | 0% | – | 0.5x | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。